Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indicators02:39

Indicators

61.1K
Certain organic substances change color in dilute solution when the hydronium ion concentration reaches a particular value. For example, phenolphthalein is a colorless substance in any aqueous solution with a hydronium ion concentration greater than 5.0 × 10−9 M (pH < 8.3). In more basic solutions where the hydronium ion concentration is less than 5.0 × 10−9 M (pH > 8.3), it is red or pink. Substances such as phenolphthalein, which can be used to determine the pH of a solution, are...
61.1K
Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

11.0K
Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
11.0K
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

107.8K
Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
107.8K
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

4.1K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
4.1K
Mechanical Ventilation I: Indication and Settings01:29

Mechanical Ventilation I: Indication and Settings

2.9K
Mechanical ventilation is a life-saving technique for managing acute respiratory failure and other respiratory complications. The process involves using a machine known as a ventilator to supply oxygen to the lungs and assist in removing carbon dioxide. It serves as a bridge to long-term mechanical ventilation or a temporary measure until ventilatory support is discontinued. The ventilator can maintain this function for a prolonged period, providing critical support for patients until they can...
2.9K
Respiratory Assessment: Purpose and Indications01:19

Respiratory Assessment: Purpose and Indications

1.8K
Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same author

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.

European journal of nuclear medicine and molecular imaging·2026
Same author

Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

The Lancet. Oncology·2026
Same author

Unmasking the unexpected: a rare case of rheumatic heart disease.

Cardiology in the young·2026
Same author

The Performance of Prognostic Measures for Survival in Spinal Metastatic Disease in Light of Modern Advancements in Medical and Surgical Management.

Spine·2026

Related Experiment Video

Updated: Feb 14, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.3K

PSMA PET/CT-Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the

Koichiro Kimura1, Vishnu Murthy2, Andrew F Voter3

  • 1Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, Los Angeles, California; koichirokimura@mednet.ucla.edu.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|February 12, 2026
PubMed
Summary

Baseline total tumor SUVmean on PSMA PET/CT is a strong predictor of treatment success for metastatic castration-resistant prostate cancer patients receiving Lu-PSMA therapy. Higher SUVmean values correlate with improved progression-free and overall survival, aiding in patient selection.

Keywords:
177Lu-PSMAPSMA PET/CTSUVmeanimaging biomarkermetastatic castration-resistant prostate cancer

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K
Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.4K

Related Experiment Videos

Last Updated: Feb 14, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.3K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K
Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.4K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceuticals

Background:

  • Prostate-specific membrane antigen (PSMA) PET/CT indicators are explored for predicting response to 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer (mCRPC).
  • Evaluating these indicators in a U.S. Expanded-Access Program cohort is crucial for real-world application.

Purpose of the Study:

  • To assess and compare the prognostic performance of pretherapeutic visual and quantitative PSMA PET/CT indicators.
  • To determine if these indicators predict outcomes like PSA50, PSA progression-free survival (PFS), and overall survival (OS) in mCRPC patients treated with 177Lu-PSMA.

Main Methods:

  • Retrospective analysis of 88 mCRPC patients from 3 U.S. institutions in the Expanded-Access Program.
  • Assessed visual (e.g., tumor-to-salivary gland ratio) and quantitative metrics (e.g., total tumor SUVmean, total lesion uptake).
  • Analyzed associations with PSA50, PSA PFS, and OS using univariate/multivariate models and concordance index.

Main Results:

  • Median follow-up was 36.1 months; PSA50 rate was 43%, median PSA PFS was 4.5 months, and median OS was 12.5 months.
  • Total tumor SUVmean demonstrated the highest predictive accuracy for PSA50 (AUC, 0.81).
  • Higher total tumor SUVmean independently predicted improved PSA PFS (HR, 0.58) and OS (HR, 0.54) in multivariate analyses, outperforming clinical variables alone.

Conclusions:

  • Baseline total tumor SUVmean on PSMA PET/CT offers independent prognostic value beyond clinical factors.
  • Total tumor SUVmean can serve as a biomarker for patient selection and personalized treatment with 177Lu-PSMA therapy.
  • This metric aids in optimizing treatment strategies for mCRPC patients.